The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial
Open accessAbstract
Importance: The humanized monoclonal antibody atezolizumab targets programmed death-ligand 1 and has demonstrated durable single-agent activity in a subset of metastatic triple-negative breast cancers. To extend the observed activity, combinatorial approaches are being tested with standard cytotoxic chemotherapies known to induce immunogenic tumor cell death. Objective: To examine the safety, tolerability, and preliminary clinical activity of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancers. Design, Setting, and Participants: This phase 1b multicohort study enrolled 33 women with stage IV or locally recurrent triple-negative breast cancers and 0 to 2 lines of prior chemotherapy in the metastatic setting from December 8, 2014, to April 30, 2017, at 11 sites in the United States. The median follow-up was 24.4 months (95% CI, 22.1-28.8 months). Interventions: Patients received concurrent intravenous atezolizumab and intravenous nab-paclitaxel (minimum 4 cycles). Main Outcomes and Measures: The primary end point was safety and tolerability. Secondary end points included best overall response rate by Response Evaluation Criteria in Solid Tumors, version 1.1; objective response rate; duration of response; disease control rate; progression-free survival; overall survival; and biomarker analyses. Results: The 33 women had a median age of 55 years (range, 32-84 years) and received 1 or more doses of atezolizumab. All patients (100%) experienced at least 1 treatment-related adverse event, 24 patients (73%) experienced grade 3/4 adverse events, and 7 patients (21%) had grade 3/4 adverse events of special interest. No deaths were related to study treatment. The objective response rate was 39.4% (95% CI, 22.9%-57.9%), and the median duration of response was 9.1 months (95% CI, 2.0-20.9 months). The disease control rate was 51.5% (95% CI, 33.5%-69.2%). Median progression-free survival and overall survival were 5.5 months (95% CI, 5.1-7.7 months) and 14.7 months (95% CI, 10.1-not estimable), respectively. Concurrent nab-paclitaxel neither significantly changed biomarkers of the tumor immune microenvironment (programmed death-ligand 1, tumor-infiltrating lymphocytes, CD8) nor impaired atezolizumab systemic immune activation (expansion of proliferating CD8+ T cells, increase of CXCL10 chemokine). Conclusions and Relevance: In this phase 1b trial for metastatic triple-negative breast cancers, the combination of atezolizumab plus nab-paclitaxel had a manageable safety profile. Antitumor responses were observed, including in patients previously treated with a taxane. Trial Registration: ClinicalTrials.gov identifier: NCT01633970.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Self-citationAtezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., Van den Eynden, G., Baehner, F. L., Penault-Llorca, F., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu450 · Cited by 3,113
Self-citationFehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32455-2 · Cited by 2,199
Immunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
Loi, S., Sirtaine, N., Piette, F., Salgado, R., Viale, G., Van Eenoo, F., Rouas, G., Francis, P., Crown, J. P. A., Hitre, E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0902 · Cited by 1,632
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477
PD-L1 Expression in Triple-Negative Breast Cancer
Mittendorf, E. A., Philips, A. V., Meric-Bernstam, F., Qiao, N., Wu, Y., Harrington, S., Su, X., Wang, Y., Gonzalez-Angulo, A. M., Akcakanat, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0127 · Cited by 1,396
Adams, S., Gray, R. J., Demaria, S., Goldstein, L., Perez, E. A., Shulman, L. N., Martino, S., Wang, M., Jones, V. E., Saphner, T. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.55.0491 · Cited by 1,299
Self-citationLoi, S., Michiels, S., Salgado, R., Sirtaine, N., Jose, V., Fumagalli, D., Kellokumpu-Lehtinen, P.-L., Bono, P., Kataja, V., Desmedt, C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu112 · Cited by 1,256
Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Apetoh, L., Rébé, C., & Ghiringhelli, F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3690 · Cited by 1,245
Clonal evolution in breast cancer revealed by single nucleus genome sequencing
Wang, Y., Waters, J., Leung, M. L., Unruh, A., Roh, W., Shi, X., Chen, K., Scheet, P., Vattathil, S., Liang, H., et al. (2014) · Nature · doi:10.1038/nature13600 · Cited by 1,029
Denkert, C., von Minckwitz, G., Brase, J. C., Sinn, B. V., Gade, S., Kronenwett, R., Pfitzner, B. M., Salat, C., Loi, S., Schmitt, W. D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.1967 · Cited by 1,026
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Pfirschke, C., Engblom, C., Rickelt, S., Cortez-Retamozo, V., Garris, C., Pucci, F., Yamazaki, T., Poirier-Colame, V., Newton, A., Redouane, Y., et al. (2016) · Immunity · doi:10.1016/j.immuni.2015.11.024 · Cited by 952
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Tutt, A., Tovey, H., Cheang, M. C. U., Kernaghan, S., Kilburn, L., Gazinska, P., Owen, J., Abraham, J., Barrett, S., Barrett-Lee, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0009-7 · Cited by 912
Triple-Negative Breast Cancer: An Unmet Medical Need
Hudis, C. A., & Gianni, L. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-s1-01 · Cited by 780
Emens, L. A., Cruz, C., Eder, J. P., Braiteh, F., Chung, C., Tolaney, S. M., Kuter, I., Nanda, R., Cassier, P. A., Delord, J.-P., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4224 · Cited by 766
Self-citationWallin, J. J., Bendell, J. C., Funke, R., Sznol, M., Korski, K., Jones, S., Hernandez, G., Mier, J., He, X., Hodi, F. S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12624 · Cited by 713
Self-citationChen, D. S., Irving, B. A., & Hodi, F. S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1362 · Cited by 654
Muenst, S., Schaerli, A. R., Gao, F., Däster, S., Trella, E., Droeser, R. A., Muraro, M. G., Zajac, P., Zanetti, R., Gillanders, W. E., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2988-5 · Cited by 558
Li, X., Yang, J., Peng, L., Sahin, A. A., Huo, L., Ward, K. C., O’Regan, R., Torres, M. A., & Meisel, J. L. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-4059-6 · Cited by 540
Gradishar, W. J., Krasnojon, D., Cheporov, S., Makhson, A. N., Manikhas, G. M., Clawson, A., & Bhar, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.5397 · Cited by 341
Dieci, M. V., Mathieu, M. C., Guarneri, V., Conte, P., Delaloge, S., Andre, F., & Goubar, A. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv239 · Cited by 310
Miles, D. W., Diéras, V., Cortés, J., Duenne, A.-A., Yi, J., & O'Shaughnessy, J. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt276 · Cited by 228
Rugo, H. S., Barry, W. T., Moreno-Aspitia, A., Lyss, A. P., Cirrincione, C., Leung, E., Mayer, E. L., Naughton, M., Toppmeyer, D., Carey, L. A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5298 · Cited by 222
Emens, L. A., Braiteh, F. S., Cassier, P., Delord, J.-P., Eder, J. P., Fasso, M., Xiao, Y., Wang, Y., Molinero, L., Chen, D. S., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-2859 · Cited by 211
Self-citationTriple Negative Breast Cancer – An Overview
Akshata Desai, K. A. (2012) · Hereditary Genetics · doi:10.4172/2161-1041.s2-001 · Cited by 200
Loi, S., Adams, S., Schmid, P., Cortés, J., Cescon, D. W., Winer, E. P., Toppmeyer, D. L., Rugo, H. S., De Laurentiis, M., Nanda, R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx440.005 · Cited by 181
Self-citationAdams, S., Schmid, P., Rugo, H. S., Winer, E. P., Loirat, D., Awada, A. H., Cescon, D. W., Iwata, H., Campone, M., Nanda, R., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.1008 · Cited by 132
Self-citationPowles, T. B., Vogelzang, N. J., Fine, G. D., Eder, J. P., Braiteh, F. S., Loriot, Y., Cruz, C., Joaquim Bellmunt, B., Burris, H. A., Teng, S.-L. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.5011 · Cited by 96
Atkins, M. B., McDermott, D. F., Powles, T. B., Motzer, R. J., Rini, B. I., Fong, L. H., Joseph, R. W., Pal, S. K., Sznol, M., Hainsworth, J. D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4505 · Cited by 75
Triple Negative Breast Cancer – Overview
Garbino, C. (2012) · Journal of the Senologic International Society · doi:10.7170/jsis.v1i2.21 · Cited by 74
Adams, S., Loi, S., Toppmeyer, D., Cescon, D. W., Laurentiis, M. D., Nanda, R., Winer, E. P., Mukai, H., Tamura, K., Armstrong, A. C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.1088 · Cited by 74
Self-citationLiu, S. V., Camidge, D. R., Gettinger, S. N., Giaccone, G., Heist, R. S., Hodi, F. S., Ready, N., Zhang, W., Wallin, J. J., Funke, R. P., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.06.033 · Cited by 51
Self-citationWallin, J. J., Pishvaian, M. J., Hernandez, G., Yadav, M., Jhunjhunwala, S., Delamarre, L., He, X., Powderly, J. D., Lieu, C. H., Eckhardt, S., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-2651 · Cited by 41
Self-citationLoi, S., Drubay, D., Adams, S., Francis, P., Joensuu, H., Dieci, M., Badve, S., Demaria, S., Gray, R., Piccart, M. J., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.sabcs15-s1-03 · Cited by 35
Self-citationJoaquim Bellmunt, B., Petrylak, D. P., Powles, T. B., Braiteh, F., Vogelzang, N. J., Cruz, C., Burris, H. A., Eder, J. P., Fine, G. D., Teng, M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu337.1 · Cited by 13
Cited by
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
Bianchini, G., De Angelis, C., Licata, L., & Gianni, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00565-2 · Cited by 1,382
Schmid, P., Rugo, H. S., Adams, S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Henschel, V., Molinero, L., Chui, S. Y., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30689-8 · Cited by 1,216
Self-citationVoorwerk, L., Slagter, M., Horlings, H. M., Sikorska, K., van de Vijver, K. K., de Maaker, M., Nederlof, I., Kluin, R. J. C., Warren, S., Ong, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0432-4 · Cited by 905
Tumor-infiltrating lymphocytes in the immunotherapy era
Paijens, S. T., Vledder, A., de Bruyn, M., & Nijman, H. W. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00565-9 · Cited by 880
Miles, D., Gligorov, J., André, F., Cameron, D., Schneeweiss, A., Barrios, C., Xu, B., Wardley, A., Kaen, D., Andrade, L., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.05.801 · Cited by 734
Self-citation
Metadata
- Authors
- Adams, S., Diamond, J. R., Hamilton, E., Pohlmann, P. R., Tolaney, S. M., Chang, C.-W., Zhang, W., Iizuka, K., Foster, P. G., Molinero, L., Funke, R., & Powderly, J.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2019-03-01
- Volume
- 5
- Issue
- 3
- Pages
- 334
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2897523860
- Cited by
- 288
- References
- 42
- FWCI
- 11.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.